About this Journal Submit a Manuscript Table of Contents
Advances in Urology
Volume 2014 (2014), Article ID 271304, 4 pages
http://dx.doi.org/10.1155/2014/271304
Clinical Study

Impact of Benign Prostatic Hyperplasia Pharmacological Treatment on Transrectal Prostate Biopsy Adverse Effects

1Urology Division, Faculty of Medicine, Pontifical Catholic University of Campinas (PUC-Campinas), 13083-970 Campinas, SP, Brazil
2Dr. Mario Gatti County Hospital, 13083-970 Campinas, SP, Brazil
3Urology Division, Department of Surgery, University of Campinas (UNICAMP), 13083-970 Campinas, SP, Brazil
4Department of Genetics, University of Campinas (UNICAMP), 13083-970 Campinas, SP, Brazil
5Department of Urology, School of Medical Sciences, University of Campinas (UNICAMP), 13083-970 Campinas, SP, Brazil

Received 6 February 2014; Revised 30 March 2014; Accepted 13 April 2014; Published 28 April 2014

Academic Editor: Maxwell V. Meng

Copyright © 2014 Marina Zamuner et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. American Cancer Society, Overview: Prostate Cancer. How Many Men Get Prostate Cancer?, 2013, http://www.cancer.org/acs/groups/cid/documents/webcontent/003072-pdf.pdf.
  2. F. Rabbani, N. Stroumbakis, B. R. Kava, M. S. Cookson, and W. R. Fair, “Incidence and clinical significance of false-negative sextant prostate biopsies,” The Journal of Urology, vol. 37, no. 6, p. 660, 1998. View at Scopus
  3. I. M. Thompson, D. K. Pauler, P. J. Goodman et al., “Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter,” The New England Journal of Medicine, vol. 350, no. 22, pp. 2239–2321, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. M. J. Ahrens, P. A. Bertin, E. F. Vonesh, T. J. Meade, W. J. Catalona, and D. Georganopoulou, “PSA enzymatic activity: a new biomarker for assessing prostate cancer aggressiveness,” Prostate, vol. 73, no. 16, pp. 1731–1737, 2013. View at Publisher · View at Google Scholar
  5. M. D. Rifkin, A. A. Alexander, J. Pisarchick, and T. Matteucci, “Palpable masses in the prostate: superior accuracy of US-guided biopsy compared with accuracy of digitally guided biopsy,” Radiology, vol. 179, no. 1, pp. 41–42, 1991. View at Scopus
  6. S. Loeb, A. Vellekoop, H. U. Ahmed et al., “Systematic review of complications of prostate biopsy,” European Urology, vol. 64, no. 6, pp. 876–892, 2013. View at Publisher · View at Google Scholar
  7. P.-F. Shen, Y.-C. Zhu, W.-R. Wei et al., “The results of transperineal versus transrectal prostate biopsy: a systematic review and meta-analysis,” Asian Journal of Andrology, vol. 14, no. 2, pp. 310–315, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Kravchick, S. Cytron, A. Mamonov, R. Peled, and L. Linov, “Effect of short-term dutasteride therapy on prostate vascularity in patients with benign prostatic hyperplasia: a pilot study,” Urology, vol. 73, no. 6, pp. 1274–1278, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. C.-H. Liao, J.-H. Guh, S.-C. Chueh, and H.-J. Yu, “Anti-angiogenic effects and mechanism of prazosin,” Prostate, vol. 71, no. 9, pp. 976–984, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Keledjian, A. Borkowski, G. Kim, J. T. Isaacs, S. C. Jacobs, and N. Kyprianou, “Reduction of human prostate tumor vascularity by the α1-adrenoceptor antagonist terazosin,” Prostate, vol. 48, no. 2, pp. 71–78, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Angulo, P. Cuevas, A. Fernández et al., “Tadalafil enhances the inhibitory effects of tamsulosin on neurogenic contractions of human prostate and bladder neck,” The Journal of Sexual Medicine, vol. 9, no. 9, pp. 2293–2306, 2012. View at Publisher · View at Google Scholar
  12. L. O. Reis, E. L. Zani, J. C. Alonso, F. A. Simões, R. F. Rejowski, and U. Ferreira, “Does the criterion for prostate biopsy indication impact its accuracy? A prospective population-based outpatient clinical setting study,” Actas Urologicas Espanolas, vol. 35, no. 1, pp. 10–14, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. V. C. N. Junqueira, O. Zogbi, A. Cologna et al., “Is a visible (hypoechoic) lesion at biopsy an independent predictor of prostate cancer outcome?” Ultrasound in Medicine and Biology, vol. 38, no. 10, pp. 1689–1694, 2012. View at Publisher · View at Google Scholar
  14. L. O. Reis, J. A. S. Reinato, D. C. Silva, W. E. Matheus, F. Denardi, and U. Ferreira, “The impact of core biopsy fragmentation in prostate cancer,” International Urology and Nephrology, vol. 42, no. 4, pp. 965–969, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Anastasiadis, L. Zapała, E. Cordeiro, A. Antoniewicz, G. Dimitriadis, and T. De Reijke, “Complications of prostate biopsy,” Expert Review of Anticancer Therapy, vol. 13, no. 7, pp. 829–837, 2013. View at Publisher · View at Google Scholar
  16. A. Campeggi, I. Ouzaid, E. Xylinas et al., “Acute bacterial prostatitis after transrectal ultrasound-guided prostate biopsy: epidemiological, bacteria and treatment patterns from a 4-year prospective study,” International Journal of Urology, vol. 21, no. 2, pp. 152–155, 2013. View at Publisher · View at Google Scholar
  17. G. I. Pinkhasov, Y.-K. Lin, R. Palmerola et al., “Complications following prostate needle biopsy requiring hospital admission or emergency department visits—experience from 1000 consecutive cases,” BJU International, vol. 110, pp. 369–374, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Peyromaure, V. Ravery, A. Messas, M. Toublanc, L. Boccon-Gibod, and L. Boccon-Gibod, “Pain and morbidity of an extensive prostate 10-biopsy protocol: a prospective study in 289 patients,” Journal of Urology, vol. 167, no. 1, pp. 218–221, 2002. View at Scopus
  19. Ö. L. Özdal, C. Özden, K. Benli, S. Gökkaya, S. Bulut, and A. Memiş, “Effect of short-term finasteride therapy on peroperative bleeding in patients who were candidates for transurethral resection of the prostate (TUR-P): a randomized controlled study,” Prostate Cancer and Prostatic Diseases, vol. 8, no. 3, pp. 215–218, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. A. L. Pastore, S. Mariani, F. Barrese et al., “Transurethral resection of prostate and the role of pharmacological treatment with dutasteride in decreasing surgical blood loss,” Journal of Endourology, vol. 27, no. 1, pp. 68–70, 2013. View at Publisher · View at Google Scholar
  21. R. G. Hahn, T. Fagerström, T. L. J. Tammela et al., “Blood loss and postoperative complications associated with transurethral resection of the prostate after pretreatment with dutasteride,” BJU International, vol. 99, no. 3, pp. 587–594, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. J. A. Arratia-Maqueo, R. Garza-Cortés, L. S. Gómez-Guerra, and J. R. Cortés-Gonzlez, “Effect of one month treatment with dutasteride on transurethral resection of the prostate,” Actas Urologicas Espanolas, vol. 34, no. 10, pp. 866–869, 2010. View at Publisher · View at Google Scholar · View at Scopus